FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017399995> ?p ?o ?g. }

• W2017399995 endingPage "e64570" @default.
• W2017399995 startingPage "e64570" @default.
• W2017399995 abstract "Fatty acid synthase (FASN) expression is elevated in several cancers, and this over-expression is associated with poor prognosis. Inhibitors of FASN, such as orlistat, reportedly show antitumor effects against cancers that over-express FASN, making FASN a promising therapeutic target. However, large variations in FASN expression levels in individual tumors have been observed, and methods to predict FASN-targeted therapy outcome before treatment are required to avoid unnecessary treatment. In addition, how FASN inhibition affects tumor progression remains unclear. Here, we showed the method to predict FASN-targeted therapy outcome using radiolabeled acetate uptake and presented mechanisms of FASN inhibition with human prostate cancer cell lines, to provide the treatment strategy of FASN-targeted therapy. We revealed that tumor uptake of radiolabeled acetate reflected the FASN expression levels and sensitivity to FASN-targeted therapy with orlistat in vitro and in vivo. FASN-targeted therapy was noticeably effective against tumors with high FASN expression, which was indicated by high acetate uptake. To examine mechanisms, we established FASN knockdown prostate cancer cells by transduction of short-hairpin RNA against FASN and investigated the characteristics by analyses on morphology and cell behavior and microarray-based gene expression profiling. FASN inhibition not only suppressed cell proliferation but prevented pseudopodia formation and suppressed cell adhesion, migration, and invasion. FASN inhibition also suppressed genes involved in production of intracellular second messenger arachidonic acid and androgen hormones, both of which promote tumor progression. Collectively, our data demonstrated that uptake of radiolabeled acetate is a useful predictor of FASN-targeted therapy outcome. This suggests that [1-(11)C]acetate positron emission tomography (PET) could be a powerful tool to accomplish personalized FASN-targeted therapy by non-invasive visualization of tumor acetate uptake and selection of responsive tumors. FASN-targeted therapy could be an effective treatment to suppress multiple steps related to tumor progression in prostate cancers selected by [1-(11)C]acetate PET." @default.
• W2017399995 created "2016-06-24" @default.
• W2017399995 creator A5009564545 @default.
• W2017399995 creator A5013678238 @default.
• W2017399995 creator A5020494950 @default.
• W2017399995 creator A5023174439 @default.
• W2017399995 creator A5023878612 @default.
• W2017399995 creator A5033938344 @default.
• W2017399995 creator A5038612225 @default.
• W2017399995 creator A5054333715 @default.
• W2017399995 creator A5058648308 @default.
• W2017399995 creator A5061746144 @default.
• W2017399995 creator A5068928963 @default.
• W2017399995 creator A5070281672 @default.
• W2017399995 creator A5076747974 @default.
• W2017399995 creator A5078877030 @default.
• W2017399995 creator A5090371551 @default.
• W2017399995 date "2013-05-31" @default.
• W2017399995 modified "2023-10-14" @default.
• W2017399995 title "Fatty Acid Synthase Is a Key Target in Multiple Essential Tumor Functions of Prostate Cancer: Uptake of Radiolabeled Acetate as a Predictor of the Targeted Therapy Outcome" @default.
• W2017399995 cites W1486552182 @default.
• W2017399995 cites W1989686918 @default.
• W2017399995 cites W2001576995 @default.
• W2017399995 cites W2005281513 @default.
• W2017399995 cites W2006104470 @default.
• W2017399995 cites W2009008628 @default.
• W2017399995 cites W2011237927 @default.
• W2017399995 cites W2015168005 @default.
• W2017399995 cites W2026185210 @default.
• W2017399995 cites W2026581504 @default.
• W2017399995 cites W2036897455 @default.
• W2017399995 cites W2039163595 @default.
• W2017399995 cites W2040827725 @default.
• W2017399995 cites W2041824087 @default.
• W2017399995 cites W2042580589 @default.
• W2017399995 cites W2055319474 @default.
• W2017399995 cites W2060744991 @default.
• W2017399995 cites W2062785709 @default.
• W2017399995 cites W2065439764 @default.
• W2017399995 cites W2069500637 @default.
• W2017399995 cites W2087940936 @default.
• W2017399995 cites W2090358734 @default.
• W2017399995 cites W2092978855 @default.
• W2017399995 cites W2101995865 @default.
• W2017399995 cites W2102774752 @default.
• W2017399995 cites W2104424545 @default.
• W2017399995 cites W2107277218 @default.
• W2017399995 cites W2112304596 @default.
• W2017399995 cites W2116706401 @default.
• W2017399995 cites W2119237939 @default.
• W2017399995 cites W2127775495 @default.
• W2017399995 cites W2130086658 @default.
• W2017399995 cites W2138478012 @default.
• W2017399995 cites W2141378022 @default.
• W2017399995 cites W2146033919 @default.
• W2017399995 cites W2153178365 @default.
• W2017399995 cites W2153747430 @default.
• W2017399995 cites W2154893263 @default.
• W2017399995 cites W2159320478 @default.
• W2017399995 cites W2161250342 @default.
• W2017399995 cites W2162140736 @default.
• W2017399995 cites W2166724224 @default.
• W2017399995 cites W2168963947 @default.
• W2017399995 doi "https://doi.org/10.1371/journal.pone.0064570" @default.
• W2017399995 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3669310" @default.
• W2017399995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23741342" @default.
• W2017399995 hasPublicationYear "2013" @default.
• W2017399995 type Work @default.
• W2017399995 sameAs 2017399995 @default.
• W2017399995 citedByCount "89" @default.
• W2017399995 countsByYear W20173999952014 @default.
• W2017399995 countsByYear W20173999952015 @default.
• W2017399995 countsByYear W20173999952016 @default.
• W2017399995 countsByYear W20173999952017 @default.
• W2017399995 countsByYear W20173999952018 @default.
• W2017399995 countsByYear W20173999952019 @default.
• W2017399995 countsByYear W20173999952020 @default.
• W2017399995 countsByYear W20173999952021 @default.
• W2017399995 countsByYear W20173999952022 @default.
• W2017399995 countsByYear W20173999952023 @default.
• W2017399995 crossrefType "journal-article" @default.
• W2017399995 hasAuthorship W2017399995A5009564545 @default.
• W2017399995 hasAuthorship W2017399995A5013678238 @default.
• W2017399995 hasAuthorship W2017399995A5020494950 @default.
• W2017399995 hasAuthorship W2017399995A5023174439 @default.
• W2017399995 hasAuthorship W2017399995A5023878612 @default.
• W2017399995 hasAuthorship W2017399995A5033938344 @default.
• W2017399995 hasAuthorship W2017399995A5038612225 @default.
• W2017399995 hasAuthorship W2017399995A5054333715 @default.
• W2017399995 hasAuthorship W2017399995A5058648308 @default.
• W2017399995 hasAuthorship W2017399995A5061746144 @default.
• W2017399995 hasAuthorship W2017399995A5068928963 @default.
• W2017399995 hasAuthorship W2017399995A5070281672 @default.
• W2017399995 hasAuthorship W2017399995A5076747974 @default.
• W2017399995 hasAuthorship W2017399995A5078877030 @default.
• W2017399995 hasAuthorship W2017399995A5090371551 @default.
• W2017399995 hasBestOaLocation W20173999951 @default.
• W2017399995 hasConcept C121608353 @default.

• next